{"entity":{"id":"r-5780","kind":"drug","name":"R-5780","aka":["R-5780-01"],"tldr":"R-5780 is an experimental pill from Rise Therapeutics designed to help immunotherapy drugs work in tumours that resist them. It is in an early trial with PD-1 inhibitors.","summary":"R-5780 is an oral immunotherapy developed by Rise Therapeutics to enhance immune checkpoint inhibitor activity in tumours refractory to them or classically unresponsive. It is being tested in a phase 1 trial with PD-1 inhibitors in patients with solid tumours (NCT06398418), sponsored by Rise. No results have been published.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov: NCT06398418","url":"https://clinicaltrials.gov/study/NCT06398418"},{"label":"Rise Therapeutics: pipeline","url":"https://risetherapeutics.com/pipeline/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["microbiome-modulation-io"],"targets":[],"drugs":[],"companies":["rise-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"R-5780","modality":"Oral microbial immunotherapy","mechanism":"Delivers secreted antigen A (SagA) from Enterococcus faecium to engage microbiome-associated pattern recognition receptors in the gut and potentiate PD-1 and CTLA-4 blockade, as the developer's award abstract describes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/r-5780/","neighbours":{"technology":[{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/"}],"company":[{"id":"rise-therapeutics","kind":"company","name":"Rise Therapeutics","route":"/companies/rise-therapeutics/"}]}}